Oral Thrombin Inhibitor Ximelagatran given to Patients as Prolonged Prophylaxis after a Six-month Anticoagulation Treatment for Venous Thromboembolism. An International Multicentre Double-blind Placebo Controlled Study (THRIVE III)

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].